The Future of Oncology: BiTEs and ADCs Explained for MBBS & NEET PG

Welcome to this high-yield oncology lecture on BiTE therapy and Antibody Drug Conjugates (ADCs) explained in a simple and exam-focused manner.
In this session, we cover:
✅ Blinatumomab mechanism of action
✅ Inotuzumab Ozogamicin explained
✅ BiTE vs ADC comparison
✅ CD19, CD22 and targeted therapy basics
✅ Cytokine Release Syndrome (CRS)
✅ ICANS neurotoxicity
✅ VOD/SOS and ADC toxicities
✅ Board exam style MCQs and clinical pearls
✅ Relapsed/Refractory B-ALL treatment concepts
✅ Modern molecular precision oncology
Perfect for:
• MBBS students
• NEET PG aspirants
• INICET preparation
• USMLE students
• Hematology/Oncology residents
• Medical educators
If this lecture helped you, don’t forget to Like 👍 Share 📤 and Subscribe 🔔 for more high-yield medicine and oncology content.
timecodes,
0:00 - Precision oncology
2:12 - The problem
4:12 - Selecting the Right Targeted Agents
6:41 - Why Blinatomumab fits Rohan’s profile
8:03 - Engineering a lethal immune system
9:56 - The Trojan Horse of Cancer therapy
11:38 - Intracellular Annihilation
13:27 - Head to Head Comparison
15:50 - Expanding Targets beyond Leukaemia
17:30 - BiTE Toxicities
19:32 - Managing Payload collateral damage
22:10 - Board Exam Mastery
24:07 - High Yield Oncology Pearls
26:29 - The Future is Molecular Precision
27:53 - Thankyouu
#Oncology #Blinatumomab #ADC #BiTE #CancerTherapy #Hematology #BALL #USMLE #NEETPG #INICET #MedicalEducation #TargetedTherapy #ICANS #CRS #AntibodyDrugConjugate #MedicineLecture #MedicalStudents #OncologyLecture #CancerImmunotherapy #MBBS

Видео The Future of Oncology: BiTEs and ADCs Explained for MBBS & NEET PG канала ANJALIMED@24